Nov. 3 (Sat), 12:00-13:00
Art Hall (4F)
Advancements in our understanding of genetics have the potential tochange the practice of medicine and enable genomics-based healthcare. With streamlined workflows and advanced informatics, Illumina sequencing and array technologies and analysis services are allowing you to explore the genome more than ever before. Together, we canaddress healthcare in ways never before imagined. Visitthe Illumina booth to find out how.
Uncover rare and undiagnosed disease with next-generation sequencing, introducing TruSight® One Expanded, targeted sequencing for >86,000 exons for >6,700 genes. The TruSight®One Expandedpanel offersthe highest number of clinically relevant genes in a targeted panel on the market today, an increase of 40% in content compared to TruSight®One.
The NextSeq 550Dx instrument is FDA regulated and CE-in vitro diagnostic (IVD) marked, enabling clinical laboratories to develop and perform a wide range of applications, from NGS IVD assays using targeted panels, to clinical research applications that include methods from targeted panels to whole genomes.